Documents

SILEX laser enrichment advances toward US commercialisation, targeting major nuclear fuel market gaps.

Revenue up, net loss down, TRL-6 milestone achieved, and strong cash reserves maintained.

GLE's SILEX technology targets US nuclear fuel independence with strong market and policy tailwinds.

Revenue doubled and cash surged after a capital raise; GLE secured a major U.S. DOE award.

Major technology milestone and US support position SILEX for uranium and quantum silicon growth.

AGM showcased financial strength, tech milestones, and strategic U.S. nuclear market positioning.

Net loss widened to $42.6m as SILEX commercialisation advanced and cash reserves remained strong.

$145m equity raise funds SILEX laser enrichment commercialisation, targeting US nuclear fuel supply.

Advancing laser enrichment and quantum silicon projects, with strong US support and no debt.

GLE's SILEX technology nears commercialisation as nuclear fuel markets tighten and US support grows.

Significant advances in nuclear and quantum projects, with strong governance and financial stability.

Net loss increased to $22.7m on higher GLE costs, but key technology projects advanced and cash remains strong.

GLE accelerates SILEX technology for uranium, silicon, and isotope markets, targeting 2028 launch.